Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of FOLFOXIRI as Primary Treatment for Stage III Unresectable Locally Advanced Pancreatic Cancer

NCT02351219 is registered in ClinicalTrials.gov with Azienda Ospedaliero, Universitaria Pisana as lead sponsor.

NCT NCT02351219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of FOLFOXIRI as Primary Treatment for Stage III Unresectable Locally Advanced Pancreatic Cancer
Lead sponsor
Azienda Ospedaliero, Universitaria Pisana
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2012
Completion date
December 31, 2014
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic carcinoma stage iii